Skip to main content
ArcticZymes Technologies logo

ArcticZymes Technologies — Investor Relations & Filings

Ticker · AZT ISIN · NO0010014632 LEI · 5967007LIEEXZXGR7K47 BR Manufacturing
Open in API
Filings indexed 969 across all filing types
Latest filing 2018-06-20 Regulatory Filings
Country NO Norway
Listing BR AZT

About ArcticZymes Technologies

https://arcticzymes.com/

ArcticZymes Technologies is a life sciences company specializing in the development, manufacturing, and commercialization of novel recombinant enzymes. Leveraging over 30 years of expertise, the company discovers and engineers enzymes from cold-adapted Arctic marine organisms. These enzymes are designed to solve specific challenges in molecular applications, demonstrating high efficiency in demanding conditions such as low temperatures and high salinity. The product portfolio, including Salt Active Nucleases (SAN) and Cod Uracil-DNA Glycosylase, serves global partners in molecular diagnostics, gene therapy, vaccine production, and biomanufacturing. All products are manufactured at its ISO 13485 certified facility, ensuring high quality and performance for research and commercial use.

Recent filings

Filing Released Lang Actions
ArcticZymes launches its first Proteinase enzyme
Regulatory Filings Classification · 95% confidence The document announces the launch of a new product, 'Proteinase enzyme,' by ArcticZymes, a subsidiary of Biotec Pharmacon ASA. It details the enzyme's properties, collaborations, and market potential (IVD, molecular research, liquid biopsy). This is a product news announcement, not a formal regulatory filing (like 10-K, AR, or IR), nor is it a transcript, management change, or dividend notice. Since there is no specific category for a general product launch announcement, and it is not a report itself (Rule 2), the most appropriate general category is Regulatory Filings (RNS) as a miscellaneous announcement, although 'ER' (Earnings Release) is sometimes used loosely for major operational news, this document lacks financial results highlights. Given the options, RNS serves as the best fit for a general corporate/product news release that doesn't fit the highly specific financial or governance categories.
2018-06-20 English
BIOTEC - SUCCESSFULLY COMPLETED PRIVATE PLACEMENT
Capital/Financing Update Classification · 99% confidence The document is an announcement dated June 14, 2018, titled 'BIOTEC – SUCCESSFULLY COMPLETED PRIVATE PLACEMENT'. It details the successful completion of a private placement of new shares, raising gross proceeds of NOK 23 million. This activity directly relates to fundraising, financing, and changes in the company's capital structure (issuing new shares). This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a general regulatory filing (RNS), as it concerns a specific financing event.
2018-06-14 English
BIOTEC - SUCCESSFULLY COMPLETED PRIVATE PLACEMENT
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces the successful completion of a 'Private Placement' of new shares, raising NOK 23 million. This action involves issuing new shares and changing the capital structure, which directly relates to fundraising and financing activities. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). Since it is a substantive announcement about a completed financing event, it is classified as CAP rather than a general Regulatory Filing (RNS).
2018-06-14 English
BIOTEC - CONTEMPLATED PRIVATE PLACEMENT
Share Issue/Capital Change Classification · 99% confidence The document is an announcement dated June 14, 2018, detailing a 'contemplated private placement' of new shares (Offer Shares) by Biotec Pharmacon ASA. It specifies the number of shares, the use of proceeds, the bookbuilding period, and the expected timeline for finalization and settlement. This activity—raising capital through the issuance of new shares via a private placement—directly relates to the company's financing activities and capital structure changes. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it describes a specific, material financing event.
2018-06-14 English
BIOTEC - CONTEMPLATED PRIVATE PLACEMENT
Capital/Financing Update Classification · 99% confidence The document explicitly announces a 'CONTEMPLATED PRIVATE PLACEMENT' of new shares, detailing the number of shares, the use of proceeds (funding business opportunities), the bookbuilding process timeline, and the expected settlement dates. This activity directly relates to fundraising, financing activities, and changes in capital structure. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV).
2018-06-14 English
Biotec Pharmacon - Mandatory notification of trade
Director's Dealing Classification · 100% confidence The document is titled 'Biotec Pharmacon - Mandatory notification of trade' and explicitly states that an executive (Rolf E. Engstad, CSO) purchased shares in the company. This directly corresponds to the definition of Director's Dealing (insider trades by executives/directors). The appropriate code is DIRS.
2018-05-16 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.